🏛️ Verified NIH Record • Updated 2026-04-20
AG-120 in People With IDH1 Mutant Chondrosarcoma (NCT04278781)
Phase II Study of AG-120 in IDH1 Mutant Chondrosarcoma
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Memorial Sloan Kettering Cancer Center
🩺 Plain-English Summary (8th-Grade Level)
This study is being done to see whether AG-120 is an effective and safe treatment for people with advanced/metastatic or recurrent chondrosarcoma that has IDH1 mutation.
Who can join: Review the eligibility criteria below.
Location: Johns Hopkins Hospital (Data Collection Only) — Baltimore, Maryland
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- Johns Hopkins Hospital (Data Collection Only) — Baltimore, Maryland
- Columbia University (Specimen Analysis Only) — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- The Ohio State University (Data Collection Only) — Columbus, Ohio
- MD Anderson Cancer Center (Data Collection Only) — Houston, Texas
📞 Contact the Study Coordinator
Phone: (855) 694-6725
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chondrosarcoma
- Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial — Iowa City, Iowa
- Proton Beam Therapy for Chondrosarcoma — Houston, Texas
- Understanding Engagement Trends in Chondrosarcoma Clinical Trials — San Francisco, California
- Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration — Jacksonville, Florida
Explore by condition: All Chondrosarcoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.